Hospital-acquired and Ventilator-associated Bacterial Pneumonia (HABP/VABP)- Market Insights, Epidemiology and Market Forecast-2028

Retinitis Pigmentosa (RP)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of RP in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of RP from 2017 to 2028 segmented by the seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 2017-2028
Retinitis Pigmentosa (RP) Disease Understanding and Treatment Algorithm
Retinitis Pigmentosa (RP), which belongs to group of pigmentary retinopathies and generally starts, refers to a group of inherited retinal disorders causing retinal degeneration and blindness. RP is characterized by progressive bilateral degeneration of the rod and cone photoreceptors that leads to night blindness and progressive visual field defects. Symptoms of RP usually develop between the ages of 10 and 30, although some people experience symptoms during childhood. Symptoms vary depending on what part of the retina is affected. RP is a progressive disease, but the rate at which vision deteriorates varies for each person. Eventually, most people with the disease have a very restricted field of vision.
RP is primarily classified based on the clinical impact, as Non-syndromic, or "simple" (not affecting other organs or tissues); Syndromic (affecting other neurosensory systems such as hearing); Systemic (affecting multiple tissues. Further, the non-syndromic RP is classified on the basis of inheritance pattern, i.e. Autosomal dominant RP, Autosomal recessive RP, X-linked RP, Sporadic RP, and Lebers Congential Amaurosis. Moreover, the syndromic RP include the following subtypes: Usher syndrome and Bardet-Biedl syndrome, which are most frequently occurring among all subtypes.
The DelveInsights RP market report gives the thorough understanding of the RP by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for RP in the US, Europe, and Japan.
Retinitis Pigmentosa (RP) Epidemiology
The RP epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsights report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Diagnosed Prevalent Population, Gender- Specific Diagnosed Prevalence, Type - Specific Diagnosed Prevalence, Sub-Type Specific Diagnosed Prevalence of Syndromic RP and Sub-Type Specific Diagnosed Prevalence of Non-Syndromic RP] scenario of RP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2028.
As per DelveInsights analysis, a higher percentage of diagnosed prevalence was observed for males, in comparison to females, in all the 7MM countries, except Japan, wherein females occupy a larger patient pool than males. According to Delveinsight, the diagnosed prevalent population of RP in the 7MM was assessed to be more than 250,000 in 2017, which is expected to grow at a CAGR of XX% for the study period i.e. 2017-2028.
The estimates show highest diagnosed prevalence of RP in the United States, with an estimated 108,787 cases in 2017. Among the European 5 countries, Germany had the highest diagnosed prevalent population of RP, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed cases. Japan witnessed 28,051 prevalent cases for RP in 2017. Based on the type of RP, we have assessed that majority of the patients suffer with non-syndromic RP, while syndromic and systemic RP cases account for nearly one-fourth of the total RP population.
Furthermore, DelveInsights analysts suggests that among Syndromic and Systemic RP cases, Usher Syndrome and Bardet-Biedl syndrome are the most diagnosed prevalent subtypes of the disease. In contrast, the trend in percentage of patients for subtypes of non-syndromic RP remains variable throughout the 7MM countries. However, in all the 7MM countries, X-linked RP and Leber congenital amaurosis remain the least occurring subtypes of the disease
Retinitis Pigmentosa (RP) Drug Chapters
This segment of the RP report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Horama is developing a gene therapy candidate HORA-RPE65 in Phase III for the treatment of Autosomal Recessive RP (Non-syndromic) RPE65 RP. It is an AAV 2/4 encapsidating the human RPE65 gene under the control of the human native RPE65 promoter. The companys investigational candidate HORA-RPE65 provides the cell with a non-mutated copy of the human RPE65 gene, which can express functional RPE65 protein to halt or at least significantly delay retinal degeneration in patients with inherited retinal dystrophies caused by RPE65 gene mutations.
Nightstar Therapeutics is developing a sub-retinal AAV-based Adeno-Associated Viral Vector Encoding RP GTPase Regulator gene therapy (AAV8-RPGR) in Phase II/III for Non-syndromic X-linked Retinitis Pigmentosa (XLRP). The companys NSR-RPGR gene therapy consists of a standard AAV8 vector, including the codon-optimized human RPGR DNA. The drug candidate has already demonstrated positive outcomes in the initial Phase of Phase II/III XIRIUS trial.
jCyte is evaluating jCell human retinal progenitor cells in a Phase II trial in Adult patients with RP. The therapy uses adult retinal progenitor cells to rescue rods and cones from RP progression and possibly generate new retinal cells. The treatment requires a single intravitreal injection, which can be performed with topical anesthetic. jCyte has already completed a phase I/IIa study to determine the therapys safety. Furthermore, the drug received US FDA Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designation.
Neurotech is evaluating Renexus (NT-501) in Phase II in Participants with Syndromic RP using rates of change in cone spacing and density. Renexus (NT-501) consists of encapsulated human cells genetically modified to secrete therapeutic doses of a ciliary neurotrophic factor into the back of the eye for the treatment of RP. The drug candidate was granted orphan drug and fast-track designation by the US FDA for RP.
ReNeuron is currently leading a Phase IIa trial for the assessment of proprietary cGMP-produced, Subretinal, allogeneic, cryopreserved human retinal progenitor cells (hrpc). The company received Orphan Drug in EU and US & Fast Track Designation for in the US, for hrpc, for the treatment of RP.
Retinitis Pigmentosa (RP) Market Outlook
The RP market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Current treatments for RP are limited, but a number of developments are dignified to enter the therapeutic field. Based on randomized clinical trials with vitamins and supplements, the only widely recommended treatment is supplementation with high-dose vitamin A palmitate and fish oil, along with avoidance of vitamin E, but these adjustments only delay degeneration.
The accessibility of the retina for relatively safe surgical procedures and the immune privilege of the eye have made retinal diseases the ideal setting to use leading-edge tools, such as gene therapy and stem cell therapy, which have the potential to produce an effective treatment for some types of RP. In Gene therapy, the strategy is relatively simple for RP due to loss-of-function (usually recessively inherited).
There are no standard treatments for patients with retinitis pigmentosa. The most widely recommended treatment for many years has been supplementation with vitamin A, which some studies have shown to slow the rate of retinal deterioration.
So far, only one treatment regimen, Luxturna (Spark Therapeutics), has been approved in the United States and Europe (although not yet marketed in European countries). Luxturna, known as voretigene neparvovec-rzyl, is one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene. The therapy received approval by the US FDA in December 2017 and by the EMA in November 2018. It provides a working copy of the RPE65 gene to act in place of the mutated RPE65 gene. This working gene can restore vision and improve sight. The drug candidate is administered as a subretinal single injection below the retina in patients who have confirmed RPE65 mutations and viable retinal cells. The therapy is indicated for the treatment of patients with vision loss due to Lebers congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations.
Retinitis Pigmentosa (RP) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
To meet the unmet need of the market and to provide better versions of current treatment practices several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of RP during our forecast period, including HORA-RPE65 (Horama), AAV8-RPGR (Nightstar Therapeutics), Jcell (jCyte), Renexus (NT-501; Neurotech Pharmaceuticals), and hRPC (ReNeuron Limited). With the launch of the effective branded targeted therapies, the market is going to rise.
RP Report Insights
Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
RP Report Key Strengths
10 Years Forecast
7MM Coverage
Epidemiology Segmentation
Key Cross Competition
Market Size by Therapies
Drugs Uptake
?
RP Report Assessment
Pipeline Product Profiles
Key Products and Key Players
Market Drivers and Barriers
Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving RP market
Organize sales and marketing efforts by identifying the best opportunities for RP market
To understand the future market competition in the RP market.

List Of Tables

Table 1: Summary of Genes Implicated in RP
Table 2: Syndromic retinitis pigmentosa
Table 3: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017-2028)
Table 4: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2028)
Table 5: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2028)
Table 6: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the 7MM (2017-2028)
Table 7: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in the 7MM (2017-2028)
Table 8: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017-2028)
Table 9: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017-2028)
Table 10: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017-2028)
Table 11: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017-2028)
Table 12: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in the US (2017-2028)
Table 13: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017-2028)
Table 14: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2028)
Table 15: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2028)
Table 16: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017-2028)
Table 17: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Germany (2017-2028)
Table 18: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017-2028)
Table 19: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2028)
Table 20: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2028)
Table 21: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017-2028)
Table 22: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in France (2017-2028)
Table 23: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017-2028)
Table 24: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2028)
Table 25: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2028)
Table 26: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017-2028)
Table 27: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Italy (2017-2028)
Table 28: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017-2028)
Table 29: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2028)
Table 30: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2028)
Table 31: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017-2028)
Table 32: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Spain (2017-2028)
Table 33: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United Kingdom (2017-2028)
Table 34: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom (2017-2028)
Table 35: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom (2017-2028)
Table 36: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017-2028)
Table 37: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in the UK (2017-2028)
Table 38: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017-2028)
Table 39: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017-2028)
Table 40: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017-2028)
Table 41: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017-2028)
Table 42: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Japan (2017-2028)
Table 43: Table: Associated conditions and corresponding treatment plans for RP Patients
Table 44: Key Cross of Emerging Drugs
Table 45: Key Cross of Emerging Drugs (Contd.)
Table 46: AAV8-RPGR, Clinical Trial Description, 2019
Table 47: jCell, Clinical Trial Description, 2019
Table 48: Renexus (NT-501), Clinical Trial Description, 2019
Table 49: Cenegermin (rhNGF), Clinical Trial Description, 2019
Table 50: hRPC, Clinical Trial Description, 2019
Table 51: UshStat, Clinical Trial Description, 2019
Table 52: RST-001, Clinical Trial Description, 2019
Table 53: AAV-RPGR, Clinical Trial Description, 2019
Table 54: AAV RPE65, Clinical Trial Description, 2019
Table 55: Market Size of Retinitis Pigmentosa in 7MM in USD Million (2017-2028)
Table 56: Market Size of Retinitis Pigmentosa by therapies in the 7MM, in USD Million (2017-2028)
Table 57: The US Market Size of Retinitis Pigmentosa in USD Million (2017-2028)
Table 58: Market Size of Retinitis Pigmentosa by therapies in the US, in USD Million (2017-2028)
Table 59: Expected Launch Date of Emerging Drugs in EU-5 countries
Table 60: Germany Market Size of Retinitis Pigmentosa in USD Million (2017-2028)
Table 61: Market Size of Retinitis Pigmentosa by therapies in Germany, in USD Million (2017-2028)
Table 62: France Market Size of Retinitis Pigmentosa in USD Million (2017-2028)
Table 63: Market Size of Retinitis Pigmentosa by therapies in France, in USD Million (2017-2028)
Table 64: Italy Market Size of Retinitis Pigmentosa in USD Million (2017-2028)
Table 65: Market Size of Retinitis Pigmentosa by therapies in Italy, in USD Million (2017-2028)
Table 66: Spain Market Size of Retinitis Pigmentosa in USD Million (2017-2028)
Table 67: Market Size of Retinitis Pigmentosa by therapies in Spain, in USD Million (2017-2028)
Table 68: The UK Market Size of Retinitis Pigmentosa in USD Million (2017-2028)
Table 69: Market Size of Retinitis Pigmentosa by therapies in the UK, in USD Million (2017-2028)
Table 70: Expected Launch Date of Emerging Drugs in Japan
Table 71: Japan Market Size of Retinitis Pigmentosa in USD Million (2017-2028)
Table 72:Market Size of Retinitis Pigmentosa by therapies in Japan, in USD Million (2017-2028)

List Of Figures

Figure 1: Structure of Retina
Figure 2: Normal Eye Anatomy Versus Eye Anatomy in Retinitis Pigmentosa
Figure 3: Typical Symptoms associated with RP
Figure 4: Typical Symptoms associated with RP
Figure 5: Classification of RP
Figure 6: Specific clinical diagnosis of RP
Figure 7: Pathophysiology of RP
Figure 8: Altered Retinoid Cycle Metabolic Pathway
Figure 9: Types of non-syndromic based on inheritance pattern
Figure 10: Pattern of autosomal dominant RP inheritance
Figure 11: Pattern of autosomal recessive RP inheritance.
Figure 12: Pattern of X-linked RP inheritance
Figure 13: Altered Retinoid Cycle Metabolic Pathway
Figure 14: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the 7MM (2017-2028)
Figure 15: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2028)
Figure 16: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the 7MM (2017-2028)
Figure 17: Sub-Type Specific Diagnosed Prevalence of syndromic RP in the 7MM (2017-2028)
Figure 18: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in the 7MM (2017-2028)
Figure 19: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the US (2017-2028)
Figure 20: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the US (2017-2028)
Figure 21: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United States (2017-2028)
Figure 22: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the US (2017-2028)
Figure 23: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in the US (2017-2028)
Figure 24: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Germany (2017-2028)
Figure 25: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2028)
Figure 26: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Germany (2017-2028)
Figure 27: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Germany (2017-2028)
Figure 28: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Germany (2017-2028)
Figure 29: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in France (2017-2028)
Figure 30: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2028)
Figure 31: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in France (2017-2028)
Figure 32: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in France (2017-2028)
Figure 33: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in France (2017-2028)
Figure 34: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Italy (2017-2028)
Figure 35: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2028)
Figure 36: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Italy (2017-2028)
Figure 37: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Italy (2017-2028)
Figure 38: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Italy (2017-2028)
Figure 39: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Spain (2017-2028)
Figure 40: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2028)
Figure 41: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Spain (2017-2028)
Figure 42: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Spain (2017-2028)
Figure 43: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Spain (2017-2028)
Figure 44: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in the United Kingdom (2017-2028)
Figure 45: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom (2017-2028)
Figure 46: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa in the United Kingdom (2017-2028)
Figure 47: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in the UK (2017-2028)
Figure 48: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in the UK (2017-2028)
Figure 49: Total Diagnosed Prevalent Population of Retinitis Pigmentosa in Japan (2017-2028)
Figure 50: Gender-Specific Diagnosed Prevalence of Retinitis Pigmentosa in Japan (2017-2028)
Figure 51: Type-Specific Diagnosed Prevalence of Retinitis Pigmentosa RP in Japan (2017-2028)
Figure 52: Sub-Type Specific Diagnosed Prevalence of Syndromic & Systemic RP in Japan (2017-2028)
Figure 53: Sub-Type Specific Diagnosed Prevalence of non-syndromic RP in Japan (2017-2028)
Figure 54: Future Treatment Modalities for Retinitis Pigmentosa
Figure 55: Unmet Needs of Generalized Pustular Psoriasis
Figure 56: Market Size of Retinitis Pigmentosa in the 7MM in USD Million (2017-2028)
Figure 57: Market Size of Retinitis Pigmentosa by therapies in the 7MM, in USD Million (2017-2028)
Figure 58: Market Size of Retinitis Pigmentosa in the US, USD Millions (2017-2028)
Figure 59: Market Size of Retinitis Pigmentosa by therapies in the United States, in USD Million (2017-2028)
Figure 60: Market Size of Retinitis Pigmentosa in Germany, USD Millions (2017-2028)
Figure 61: Market Size of Retinitis Pigmentosa by therapies in Germany, in USD Million (2017-2028)
Figure 62: Market Size of Retinitis Pigmentosa in France, USD Millions (2017-2028)
Figure 63: Market Size of Retinitis Pigmentosa by therapies in France, in USD Million (2017-2028)
Figure 64: Market Size of Retinitis Pigmentosa in Italy, USD Millions (2017-2028)
Figure 65: Market Size of Retinitis Pigmentosa by therapies in Italy in USD Million (2017-2028)
Figure 66: Market Size of Retinitis Pigmentosa in Spain, USD Millions (2017-2028)
Figure 67: Market Size of Retinitis Pigmentosa by therapies in Spain in USD Million (2017-2028)
Figure 68: Market Size of Retinitis Pigmentosa in the UK, USD Millions (2017-2028)
Figure 69: Market Size of Retinitis Pigmentosa by therapies in the UK in USD Million (2017-2028)
Figure 70: Market Size of Retinitis Pigmentosa in Japan, USD Millions (2017-2028)
Figure 71: Market Size of Retinitis Pigmentosa by therapies in Japan in USD Million (2017-2028)
Figure 72: Market Drivers
Figure 73: Market Barriers

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available